End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
188.8 CNY | -2.11% | +1.28% | -3.00% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 24.01 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.00% | 2.16B | - | ||
+10.39% | 126B | A- | ||
+2.52% | 8.97B | C | ||
+38.96% | 5.56B | B+ | ||
-17.50% | 4.99B | C | ||
+8.36% | 3.44B | C- | ||
-8.84% | 2.8B | B- | ||
-7.52% | 2.18B | - | - | |
-21.88% | 1.82B | - | C- | |
-7.26% | 1.17B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688016 Stock
- Ratings Shanghai MicroPort Endovascular MedTech Co., Ltd.